BMI View: The number of new drugs approved by the FDA every year will continue to rise steadily, though
this will, at least over the short term, be at a slower rate than what was seen over the 2006-2015 period.
Due to advances in genomics and personalised medicines, ..."
BMI View: Health expenditure in the US is forecast to increase by more than 50% over the next decade. A
common misconception is that drug companies and medicine price hikes are accountable for this rise and
the downward pressure it allegedly puts on prosperity. Latest ..."
BMI View: The US pharmaceutical market is, and will continue to remain, the most attractive globally.
Due to ongoing challenges in Western Europe and emerging markets, drug companies should increasingly
prioritise the US for commercialisation efforts, as well as R&D a ..."
BMI View: The US pharmaceutical market will continue to display robust growth over the medium term
despite efforts from the public and private sectors to reduce drug spending. Many newly launched patented
drugs that have clear efficacy and safety benefits are able to ..."
BMI View: Robust US pharmaceutical market growth is due to the rising prevalence of chronic diseases,
the introduction of new products with improved efficacy and safety profiles, and sustained medicine price
rises. The country is unique among developed states as there ..."
BMI View: The US pharmaceutical market's status as the most lucrative globally is unassailable. This is
due to unparalleled healthcare access, considerable spending power, a high burden of disease, minimal
market access barriers and intense company activity. The key r ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape US". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in the U ..."
BMI View: In the face of increasing product launches within highly-competitive therapeutic areas such as
diabetes care in the US, payers are becoming ever more confident in leveraging their purchasing power
over pharmaceutical companies. With few differentiating facto ..."
BMI View: The US pharmaceutical market presents strong commercial opportunities across the industry.
Total US pharmaceutical sales reached USD347.2bn in 2013 - more than three times the size of its nearest
rival Japan. The US boasts the largest individual markets acro ..."
BMI View: The US will remain the most attractive pharmaceutical market in the world for the foreseeable
future. There is a considerable burden of disease, healthcare access is unparalleled, spending power is
growing at a sustainable rate, innovative medicines are adop ..."